OncoSil Medical

OSL.AX

Medical - Devices · Healthcare

Price

A$1.25

-0.06 (-4.21%)

Market Cap

A$38.6M

Exchange

Australian Securities Exchange

Winston Score

Winston is worried

Below-average fundamentals — multiple weak pillars.

Data as of Aug 13, 2026 · filings through Dec 31, 2025

Share count falling — buybacks

−99.0% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 1.08B (2021) → 10.9M (2025)

OncoSil Medical is a small Australian medical device company focused on treating cancer. Its main product is the OncoSil device, which delivers targeted radiation therapy directly into pancreatic tumors using tiny radioactive phosphorus-32 microparticles. The device is designed for patients with locally advanced pancreatic cancer, a disease that is very hard to treat. OncoSil has received regulatory approval in Europe and Australia.

The company earns revenue by selling its device to hospitals and cancer treatment centers, though sales remain very early-stage and small. OncoSil operates primarily in Europe and Australia, and its market cap is essentially negligible, reflecting how early it is in commercialization. The financial metrics show the company is spending far more than it earns, which is typical for pre-revenue medical device firms. The biggest risk is that pancreatic cancer treatment is a competitive and difficult market, and OncoSil must prove its device improves patient outcomes convincingly enough to drive meaningful hospital adoption.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+28.3% YoY

YoY Growth Rate

Strong revenue growth

EPS Growth

<−1,000% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$4M/ year

↑ Rising (+41% vs prior year)

359.7% of revenue

20.0x the sector average (18%)

Investing heavily in future products and technology

Insider Activity

5.5%ownership

Insiders own a meaningful stake in the company

Cash Runway

~3 months

$5M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Strong grower

OncoSil Medical is growing revenue at 28% year-over-year. The Winston Score penalises unprofitable companies, but revenue at this pace tells a different story — this is a company still in "build mode."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

-411.9%

Thin — -411.9% gross margin

Operating Margin

-889.4%

Losing money on operations — -889.4%

ROCE

-179.5%

Weak — -179.5% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+50.1%

Fast-growing sales (+50.1% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

-969.0%

Burning cash (-969.0%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.01

Conservative — low debt load (0.01)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial